ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals

放射性药物正在成为应对复杂健康挑战的下一代医疗技术，它们的制造为澳大利亚带来了巨大的经济效益。ARC靶向放射性药物先进制造研究中心(AMTAR)旨在为结合生物技术和制药科学创新的新医疗技术建立一个制造平台。该计划解决了将生物制品转化为分子放射性药物方面业界领先的挑战，建设了生物制造、放射生物学和放射化学方面的能力。该计划建立了专门的制造流水线，面向未来的生产，并确保下一代医疗技术的供应链。

Radiopharmaceuticals are emerging as next generation medical technologies for addressing complex health challenges, and their manufacture offers significant economic benefit to Australia. The ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals (AMTAR) aims to establish a manufacturing platform for new medical technologies combining innovations in biotechnology and pharmaceutical science. The program addresses industry-led challenges for translation of biologics as molecular radiopharmaceuticals, building capacity in biomanufacturing, radiobiology and radiochemistry. The program establishes a dedicated manufacturing pipeline, future-proofing production and securing supply chain of next generation medical technologies.